Swan Capital’s AbbVie ABBV Stock Holding History

Swan Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-52	Closed	-$11.9K	–	552
2025 Q4	$11.9K	Buy	+52	New	+$11.8K	﹤0.01%	160
2025 Q3	–	Sell	-30	Closed	-$5.57K	–	492
2025 Q2	$5.57K	Buy	+30	New	+$5.58K	﹤0.01%	221

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Swan Capital's ABBV Position: Q1 2026 in Review

Swan Capital sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 52 shares — an estimated $11.9K sold.

Swan Capital first reported a position in ABBV in Q2 2025 and held it in 2 quarters. The position peaked at $11.9K in Q4 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Swan Capital reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Swan Capital sold 52 AbbVie shares in Q1 2026, an estimated $11.9K.
Swan Capital first reported a position in AbbVie in Q2 2025 and held it in 2 quarters.
Swan Capital's AbbVie position peaked at $11.9K in Q4 2025.
4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Swan Capital's 13F filing for Q1 2026, filed 14 May 2026.